266 320
map: a prospective large-scale cohort study. J Magn Reson Imaging
2012;35:1414–21.
[60]
Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imag- ing and recommendations for use. Eur Urol 2016;69:41–9.
[61]
Rosenkrantz AB, Lim RP, Haghighi M, Somberg MB, Babb JS, Taneja SS. Comparison of interreader reproducibility of the Prostate Im- aging Reporting and Data System and Likert scales for evaluation of multiparametric prostate MRI. AJR Am J Roentgenol 2013;201: W612–8.
[62]
Renard-Penna R, Mozer P, Cornud F, et al. Prostate Imaging Report- ing and Data System and Likert scoring system: multiparametric MR imaging validation study to screen patients for initial biopsy. Radiology 2015;275:458–68.
[63]
Vache T, Bratan F, Mege-Lechevallier F, Roche S, Rabilloud M, Rouviere O. Characterization of prostate lesions as benign or ma- lignant at multiparametric MR imaging: comparison of three scor- ing systems in patients treated with radical prostatectomy. Radiology 2014;272:446–55.
[64]
Eggener SE, Badani K, Barocas DA, et al. Gleason 6 prostate cancer: translating biology into population health. J Urol 2015;194:626–34.[65]
Karram S, Trock BJ, Netto GJ, Epstein JI. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prosta- tectomy findings. Am J Surg Pathol 2011;35:1351–5.
[66]
Van der Kwast TH. Re: should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Eur Urol 2012;61:220.
[67]
Singh H, Canto EI, Shariat SF, et al. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol 2004;171:1850–4.
[68]
Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60:836–40.
[69]
Ahmed HU, El-Sater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389:815–22.[70]
Hansen NL, Barrett T, Koo B, et al. The influence of prostate-specific antigen density on positive and negative predictive values of multi- parametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting. BJU Int 2017;119:724–30.[71]
Washino S, Okochi T, Saito K, et al. Combination of PI-RADS score and PSA density predicts biopsy outcome in biopsy naive patients. BJU Int 2017;119:225–33.[72]
Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening?. A meta- analysis. Ann Oncol 2015;26:848–64.
[73]
van Vugt HA, Kranse R, Steyerberg EW, et al. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer 2012;48:1809–15.[74]
Mozer P, Roupret M, Le Cossec C, et al. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fu- sion compared with conventional transrectal ultrasonography- guided biopsies for the diagnosis of localised prostate cancer. BJU Int 2015;115:50–7.
[75]
Liddell H, Jyoti R, Haxhimolla HZ. mp-MRI prostate characterised PIRADS 3 lesions are associated with a low risk of clinically signifi- cant prostate cancer—a retrospective review of 92 biopsied PIRADS 3 lesions. Curr Urol 2015;8:96–100.
[76]
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16–40.
[77]
Mertan FV, Greer MD, Shih JH, et al. Prospective evaluation of the Prostate Imaging Reporting and Data System Version 2 for prostate cancer detection. J Urol 2016;196:690–6.[78]
Rosenkrantz AB, Oto A, Turkbey B, Westphalen AC. Prostate Imag- ing Reporting and Data System (PI-RADS), Version 2: a critical look. AJR Am J Roentgenol 2016;206:1179–83.[79]
Hoang Dinh A, Melodelima C, Souchon R, et al. Quantitative analysis of prostate multiparametric MR images for detection of aggressive prostate cancer in the peripheral zone: a multiple imager study. Radiology 2016;280:117–27.
[80]
Rosenkrantz AB, Ginocchio LA, Cornfeld D, et al. Interobserver reproducibility of the PI-RADS Version 2 Lexicon: a multicenter study of six experienced prostate radiologists. Radiology 2016;280:793–804.[81]
Muller BG, Shih JH, Sankineni S, et al. Prostate cancer: interobserver agreement and accuracy with the revised Prostate Imaging Report- ing and Data System at multiparametric MR imaging. Radiology 2015;277:741–50.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
266